Previous close | 5.33 |
Open | 5.26 |
Bid | 5.12 x 100 |
Ask | 5.47 x 100 |
Day's range | 5.16 - 5.66 |
52-week range | 2.85 - 15.90 |
Volume | |
Avg. volume | 139,451 |
Market cap | 63.896M |
Beta (5Y monthly) | -0.11 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.83 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 60.00 |
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.
Prenetics Global Limited (NASDAQ:PRE), a leading genomics-driven health sciences company, announces the signing of a Memorandum of Understanding (MOU), that paves the way for a strategic investment in Metavisionaries and a pioneering five-year research agreement with them and their partners Space Application Services through their Metaspace Venture. The parties will also establish a Space Innovation Lab within the UAE Space Agency. The inaugural Prenetics research cube is scheduled to on-board t
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.